SCHEMBL7740807

SCHEMBL7740807

CC(=O)N[C@H]1c2ccccc2C[C@H]1O

nearest known ligand 0.54

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.54
ALDH1A1 P00352 1/20 0.54
KMT2A Q03164 1/20 0.54
P2RX7 Q99572 1/20 0.54
MMP9 P14780 5/20 0.53
MMP1 P03956 4/20 0.53
MMP2 P08253 4/20 0.53
MMP8 P22894 4/20 0.53
NAMPT P43490 1/20 0.51
PSEN1 P49768 1/20 0.50
PSEN2 P49810 1/20 0.50
APH1B Q8WW43 1/20 0.50
NCSTN Q92542 1/20 0.50
APH1A Q96BI3 1/20 0.50
PSENEN Q9NZ42 1/20 0.50
MTNR1A P48039 1/20 0.47
MTNR1B P49286 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8838880 1.00 MEN1 (0.54) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL29676862 1.00 MEN1 (0.54) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL2442157 1.00 MEN1 (0.54) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL8017602 1.00 MEN1 (0.54) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL885306 1.00 MEN1 (0.54) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL3328510 0.85 NAMPT (0.52) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL5802535 0.85 NAMPT (0.52) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL18141994 0.85 NAMPT (0.52) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL1665424 0.85 NAMPT (0.52) MEN1ALDH1A1KMT2AP2RX7MMP9
SCHEMBL17923298 0.85 NAMPT (0.52) MEN1ALDH1A1KMT2AP2RX7MMP9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2023-01-19 US disclosed
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2021-05-11 US disclosed
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-10-29 US disclosed
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2019-02-14 US disclosed
EP-2931724-B1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS PURDUE PHARMA LP (US) 2017-01-25 EP disclosed
US-9403824-B2 Pyridonemorphinan analogs and biological activity on opioid receptors PURDUE PHARMA L.P. (US) 2016-08-02 US disclosed
US-9359317-B2 Small molecule inhibitors of HIV proteases PURDUE RESEARCH FOUNDATION (US) 2016-06-07 US disclosed
US-9340542-B2 Propellane-based compounds and the use thereof PURDUE PHARMA L.P. (US) 2016-05-17 US disclosed
US-20150203494-A1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS PURDUE PHARMA L.P. 2015-07-23 US disclosed
WO-2015097546-A1 PROPELLANE-BASED COMPOUNDS AND THEIR USE AS OPIOID RECEPTOR MODULATORS PURDUE PHARMA L.P. (US) 2015-07-02 WO disclosed
US-8980906-B2 Pyridonemorphinan analogs and biological activity on opioid receptors PURDUE PHARMA L.P. (US) 2015-03-17 US disclosed
US-20140187549-A1 Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors PURDUE PHARMA L.P. (US) 2014-07-03 US disclosed
WO-2014091295-A1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS PURDUE PHARMA L.P. (US) 2014-06-19 WO disclosed
US-20140135321-A1 SMALL MOLECULE INHIBITORS OF HIV PROTEASES NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT 2014-05-15 US disclosed
US-20110046199-A1 SMALL MOLECULE INHIBITORS OF HIV PROTEASES PURDUE RESEARCH FOUNDATION (US) 2011-02-24 US disclosed
WO-2009091941-A1 SMALL MOLECULE INHIBITORS OF HIV PROTEASES PURDUE RESEARCH FOUNDATION (US) 2009-07-23 WO disclosed
EP-0828848-B1 PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE AVECIA LTD (GB) 2002-03-27 EP disclosed
US-6087137-A PREPARING OPTICALLY ACTIVE COMPOUNDS FOR USE AS CHEMICAL INTERMEDIATES IN SYNTHESIS OF DRUGS AND AGRICULTURAL CHEMICALS ESPECIALLY ENZYME INHIBITORS TARGETED TO HUMAN IMMUNODEFICIENCY VIRUS ZENECA LIMITED (GB) 2000-07-11 US disclosed
EP-0828848-A1 PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE ZENECA LIMITED (GB) 1998-03-18 EP disclosed
WO-1996037628-A1 PREPARATION OF HYDROXY COMPOUNDS BY BIOCONVERSION WITH DIOXYGENASE ZENECA LIMITED (GB) 1996-11-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140187549-A1 Pyridonemorphinan Analogs and Biological Activity on Opioid Receptors OPRM1, OPRK1, OPRL1 MEN1 4421/4885ALDH1A1 638/4885KMT2A 1981/4885
US-20110046199-A1 SMALL MOLECULE INHIBITORS OF HIV PROTEASES SERPINB1, PRSS1, TMPRSS15 MEN1 4536/4885ALDH1A1 3984/4885KMT2A 3601/4885
US-20230019032-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 MEN1 1644/4885ALDH1A1 1598/4885KMT2A 968/4885
US-20150203494-A1 PYRIDONEMORPHINAN ANALOGS AND BIOLOGICAL ACTIVITY ON OPIOID RECEPTORS OPRM1, OPRK1, OPRL1 MEN1 4434/4885ALDH1A1 704/4885KMT2A 1879/4885
US-20140135321-A1 SMALL MOLECULE INHIBITORS OF HIV PROTEASES SERPINB1, PRSS1, TMPRSS15 MEN1 4536/4885ALDH1A1 3984/4885KMT2A 3601/4885
US-20190047990-A1 BENZOLACTAM COMPOUNDS AS PROTEIN KINASE INHIBITORS MAPK1, ALK, MAP3K1 MEN1 1644/4885ALDH1A1 1598/4885KMT2A 968/4885
US-11001575-B1 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 MEN1 1766/4885ALDH1A1 1601/4885KMT2A 997/4885
US-10457669-B2 Benzolactam compounds as protein kinase inhibitors MAPK1, ALK, MAP3K1 MEN1 1644/4885ALDH1A1 1598/4885KMT2A 968/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.